Document is current
Any future updates will be listed below
-
Authors
Svane, Maria S. https://orcid.org/0000-0002-7345-4471
Johannesen, Helle H.
Hansen, Adam E.
Martinussen, Christoffer
Bojsen-Møller, Kirstine N. https://orcid.org/0000-0003-1962-5302
Hansen, Martin Lundsgaard
Deacon, Carolyn F.
Keller, Sune H.
Klausen, Thomas L.
Loft, Annika
Kjaer, Andreas
Löfgren, Johan
Madsbad, Sten
Holst, Jens J. https://orcid.org/0000-0001-6853-3805
Wewer Albrechtsen, Nicolai J. https://orcid.org/0000-0003-4230-5753
- License Information
-
More Information
Article History
Received: 23 March 2022
Revised: 2 August 2022
Accepted: 3 August 2022
First Online: 18 August 2022
Competing interests
: NJWA has received speaker fees from MSD and Mercodia and research support from Novo Nordisk A/S, Janssen Pharmaceuticals and Mercodia.CFD has received consultancy/lecture fees from Boehringer Ingelheim, Lilly, Merck/MSD, Novo Nordisk and Novartis. SM has received research grants from Novo Nordisk and Boehringer Ingelheim; lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi Aventis; and is a member of advisory boards of AstraZeneca, Boehringer Ingelheim, Eli Lilly, Intarcia Therapeutics, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi Aventis. JJH has served on advisory panels for GlaxoSmithKline, Novo Nordisk, Zealand Pharma, AstraZeneca, MSD, Intarcia and Hanmi and acts as a consultant for Novo Nordisk, and has received research support from Merck, Sharp & Dohme. All other authors have nothing to disclosure.
